Log in

NASDAQ:AMRN - Amarin Stock Price, Forecast & News

$18.19
+0.57 (+3.23 %)
(As of 02/19/2020 04:43 AM ET)
Today's Range
$17.80
Now: $18.19
$18.30
50-Day Range
$17.62
MA: $19.36
$21.53
52-Week Range
$13.76
Now: $18.19
$26.12
Volume6.29 million shs
Average Volume7.25 million shs
Market Capitalization$6.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.08
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AMRN
CUSIPN/A
Phone353-1669-9020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$229.21 million
Book Value$0.40 per share

Profitability

Net Income$-116,440,000.00

Miscellaneous

EmployeesN/A
Market Cap$6.50 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.


Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) announced its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.03. The biopharmaceutical company had revenue of $112.40 million for the quarter, compared to analysts' expectations of $110.04 million. Amarin had a negative net margin of 17.42% and a negative return on equity of 26.67%. The firm's quarterly revenue was up 104.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.08) EPS. View Amarin's Earnings History.

When is Amarin's next earnings date?

Amarin is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Amarin.

What guidance has Amarin issued on next quarter's earnings?

Amarin issued an update on its FY 2019 Pre-Market earnings guidance on Tuesday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $425 million, compared to the consensus revenue estimate of $417.54 million.

What price target have analysts set for AMRN?

12 analysts have issued 1 year price objectives for Amarin's shares. Their forecasts range from $13.00 to $51.00. On average, they anticipate Amarin's share price to reach $27.67 in the next twelve months. This suggests a possible upside of 52.1% from the stock's current price. View Analyst Price Targets for Amarin.

What is the consensus analysts' recommendation for Amarin?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 sell rating, 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (1/13/2020)
  • 2. HC Wainwright analysts commented, "Our PT of $51 is based on equally weighted average of: (a) $47.99/share, as a 25x multiple of taxed and diluted FY29 GAAP EPS of $5.45 discounted back to and (b) an NPV of $53.14/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) Vascepa commercial ramp-up and/or peak sales not meeting our projections; and (2) further competitive disruption of the omega-3 market by branded drugs or generics and/ or OTC supplements beyond our model." (8/1/2019)
  • 3. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating on AMRN shares after the company reported its 2Q19 financials, which came in at the higher end of its 7/2 pre-announcement; however, the key update is the fact management announced it believes an adcom is unlikely for Vascepa’s sNDA now given the close proximity to its PDUFA date. As we have discussed in previous notes, we believed the lack of an adcom would further de-risk Vascepa’s sNDA – so we see this update as an incremental positive and gets us more confident in sNDA approval. Given the high probability of approval, we believe investor focus is shifting to: (1) how Vascepa’s expanded label will read; (2) commercial execution in 2020 given its planned sales force expansion and whether or not 2020 Vascepa consensus sales estimates are too low; and (3) the potential timing and outcomes of Vascepa’s ongoing ANDA litigation." (7/31/2019)

Has Amarin been receiving favorable news coverage?

News coverage about AMRN stock has been trending extremely negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amarin earned a news sentiment score of -4.1 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent press coverage is likely to have an impact on the company's share price in the next several days. View News Stories for Amarin.

Who are some of Amarin's key competitors?

What other stocks do shareholders of Amarin own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarin investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Micron Technology (MU), Canopy Growth (CGC), Alibaba Group (BABA), Square (SQ), Netflix (NFLX), Exelixis (EXEL), Bank of America (BAC) and Tesla (tsla).

Who are Amarin's key executives?

Amarin's management team includes the folowing people:
  • John F. Thero, President, Chief Executive Officer & Director
  • Derek Kalinowski, SVP-Manufacturing Operations
  • Michael W. Kalb, Chief Financial Officer & Senior Vice President
  • Steven B. Ketchum, Chief Scientific Officer & Senior Vice President
  • Craig B. Granowitz, Chief Medical Officer

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (4.49%), Perceptive Advisors LLC (1.99%), Janus Henderson Group PLC (1.01%), Lord Abbett & CO. LLC (0.68%), Broadfin Capital LLC (0.29%) and Sei Investments Co. (0.29%). Company insiders that own Amarin stock include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Institutional Ownership Trends for Amarin.

Which major investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Perceptive Advisors LLC, Broadfin Capital LLC, Nicholas Investment Partners LP, Lord Abbett & CO. LLC, Kornitzer Capital Management Inc. KS, Chartwell Investment Partners LLC and FMR LLC. Company insiders that have sold Amarin company stock in the last year include Aaron Berg, David M Stack, John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Kristine Peterson, Lars Ekman, Michael Wayne Kalb and Steven B Ketchum. View Insider Buying and Selling for Amarin.

Which major investors are buying Amarin stock?

AMRN stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Fairmount Funds Management LLC, Janus Henderson Group PLC, Partner Fund Management L.P., Private Advisor Group LLC, Crawford Lake Capital Management LLC, Gratus Capital LLC and Gladstone Capital Management LLP. View Insider Buying and Selling for Amarin.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $18.19.

How big of a company is Amarin?

Amarin has a market capitalization of $6.50 billion and generates $229.21 million in revenue each year. The biopharmaceutical company earns $-116,440,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. View Additional Information About Amarin.

What is Amarin's official website?

The official website for Amarin is http://www.amarincorp.com/.

How can I contact Amarin?

Amarin's mailing address is Block C 77 Sir John Rogerson`s Quay Grand Canal Docklands, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]


MarketBeat Community Rating for Amarin (NASDAQ AMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  772 (Vote Outperform)
Underperform Votes:  471 (Vote Underperform)
Total Votes:  1,243
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel